GLANDGland Pharma Ltd.

₹1938.6+0.79%

Market Cap

₹31,663.71 Cr

Stock P/E

41.11

ROCE

11.97%

ROE

7.82%

Book Value

₹568.49

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
GLP-1 entry with liraglutide, two contracts secured, and capacity scaled to 140 million cartridges by CY2026.
•
US launches momentum supported by multiple new products and a diversified US pipeline.

NEGATIVES

•
Cenexi turnaround remains a challenge; results have fallen short of expectations.
•
ROW growth constrained by tender misses and softer order intake.

Peers Summary

Sector Leader

Gland Pharma Ltd. showcases robust growth metrics and strong profitability compared to its peers in the Pharmaceuticals & Drugs sector, positioning it as a leader. With a low debt-equity ratio and impressive revenue growth, it stands out despite some peers exhibiting higher ROE and EPS figures. Overall, Gland Pharma is well-placed with attractive valuation metrics, making it a compelling investment choice.

Key Points

• Gland Pharma has the highest revenue growth YoY at 56.29%.
• Gland Pharma's debt-equity ratio is among the lowest at 0.0367, indicating low financial risk.
• Gland Pharma is undervalued based on its PEG ratio of 0.43, suggesting significant growth potential compared to its price.

Top Performers

Gland Pharma Ltd.

Highest revenue growth YoY at 56.29% and low debt-equity ratio at 0.0367.

Dr. Reddy's Laboratories Ltd.

Strong profitability with ROE at 21.76% and PE ratio at 15.50, making it attractive.

Mankind Pharma Ltd.

High growth trajectory with 155.25% revenue growth over 3 years and solid margins.

Explore

Watchlists

Command Palette